Article ; Online: Promising Lead Compounds in the Development of Potential Clinical Drug Candidate for Drug-Resistant Tuberculosis.
Molecules (Basel, Switzerland)
2020 Volume 25, Issue 23
Abstract: According to WHO report, globally about 10 million active tuberculosis cases, resulting in about 1.6 million deaths, further aggravated by drug-resistant tuberculosis and/or comorbidities with HIV and diabetes are present. Incomplete therapeutic regimen, ...
Abstract | According to WHO report, globally about 10 million active tuberculosis cases, resulting in about 1.6 million deaths, further aggravated by drug-resistant tuberculosis and/or comorbidities with HIV and diabetes are present. Incomplete therapeutic regimen, meager dosing, and the capability of the latent and/or active state tubercular bacilli to abide and do survive against contemporary first-line and second line antitubercular drugs escalate the prevalence of drug-resistant tuberculosis. As a better understanding of tuberculosis, microanatomy has discovered an extended range of new promising antitubercular targets and diagnostic biomarkers. However, there are still no new approved antitubercular drugs of routine therapy for several decades, except for bedaquiline, delamanid, and pretomanid approved tentatively. Despite this, innovative methods are also urgently needed to find potential new antitubercular drug candidates, which potentially decimate both latent state and active state |
---|---|
MeSH term(s) | Animals ; Antitubercular Agents/pharmacology ; Coumarins/chemistry ; Drug Design ; Humans ; Isoniazid/chemistry ; Mycobacterium tuberculosis/drug effects ; Peptides, Cyclic/chemistry ; Pharmaceutical Preparations/administration & dosage ; Pharmaceutical Preparations/chemistry ; Pore Forming Cytotoxic Proteins/chemistry ; Tuberculosis, Multidrug-Resistant/drug therapy ; Tuberculosis, Multidrug-Resistant/microbiology |
Chemical Substances | Antitubercular Agents ; Coumarins ; Peptides, Cyclic ; Pharmaceutical Preparations ; Pore Forming Cytotoxic Proteins ; griselimycin ; coumarin (A4VZ22K1WT) ; Isoniazid (V83O1VOZ8L) |
Language | English |
Publishing date | 2020-12-02 |
Publishing country | Switzerland |
Document type | Journal Article ; Review |
ZDB-ID | 1413402-0 |
ISSN | 1420-3049 ; 1431-5165 ; 1420-3049 |
ISSN (online) | 1420-3049 |
ISSN | 1431-5165 ; 1420-3049 |
DOI | 10.3390/molecules25235685 |
Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
Zs.MO 81: Show issues |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.